Observational studyJournal of advanced research2026

Microbiome-metabolome generated bile acids gatekeep infliximab efficacy in Crohn's disease by licensing M1 suppression and Treg dominance.

Le Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.